ערך בספרים למניה: ENDRA Life Sciences (NDRA)

Stable supply of diagnostic systems through a global distribution network supports the profitability of ENDRA Life Sciences (NDRA), as clearly demonstrated by the book value per share chart. The value 4.20 serves as the current parameter value. Growth depends on the certification of thermoacoustic ultrasound relative to MRI, while uninterrupted equipment production is ensured by engaging third-party electronics assemblers.

The commercial success of ENDRA Life Sciences (NDRA) depends on insurance reimbursement for TAEUS systems rather than macroeconomics. The trend in net asset value per share reflects the actual ratio of equity to the volume of issuance, allowing investors to filter out market noise and assess the intrinsic value of the business. A stable trend in this metric confirms financial stability and determines the fundamental cost of the company's capital.